This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gilda Forseter, RN; Carol Joline, RN; Gary P. Wormser, MD

Arch Intern Med. 1994;154(23):2745-2749.

Abstract
Objective
To evaluate the safety, tolerability, and acceptability of zidovudine used for prevention of human immunodeficiency virus (HIV) transmission to health care workers.

Methods
Prospective study between January 1989 and December 1992 at a suburban New York City medical center of health care workers who had percutaneous or permucosal exposures to blood or body fluids of HIV-infected patients. The zidovudine regimen offered was 200 mg orally every 4 hours for 42 days.

Results
Only 60 (53%) of 113 health care workers chose to take zidovudine, and only 21 (35%) of these health care workers completed the recommended 42-day course of therapy. Men were more likely than women to choose zidovudine therapy (P=.06), and a greater proportion of men completed the full 42 days of zidovudine therapy (P=.09). The most frequent reason for stopping treatment prematurely was clinical adverse reactions (n=18 [30%]). Overall, clinical adverse events occurred in 44 (73%) of those taking zidovudine, with the most frequent events being nausea (n=28 [47%]), headache (n=21 [35%]), and fatigue (n=18 [30%]). Selected laboratory parameters (hemoglobin level, hematocrit, alanine aminotransferase level, and white blood cell, granulocyte, and platelet counts) were compared at baseline and at week 4. Of interest, platelet counts were significantly more likely to increase by week 4 than to remain the same or decrease (P=.035). This observation may shed light on the mechanism of platelet elevation seen in zidovudine-treated patients infected with HIV. None of the laboratory changes was considered cliniclly significant. Of the 42 health care workers followed up for 3 months or longer (range, 3 to 32 months), none had undergone HIV antibody seroconversion.

Conclusions
Zidovudine therapy is poorly accepted and tolerated by health care workers, at least in the dosage regimen used in this study. Alternative prophylactic regimens are needed.

(Arch Intern Med. 1994;154:2745-2749)

Author Affiliations
From the Division of Infectious Diseases, Department of Medicine, New York Medical College (Ms Forseter and Dr Wormser), and the Acquired Immunodeficiency Syndrome Management Program, Westchester County Medical Center (Ms Joline), Valhalla, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Is Zidovudine a Prophylactic Treatment for Health Care Workers?
Coutellier et al.
Arch Intern Med 1995;155:1816-1816.
ABSTRACT